Koch Carl D, Gladwin Mark T, Freeman Bruce A, Lundberg Jon O, Weitzberg Eddie, Morris Alison
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA.
Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA 15261, USA; Pittsburgh Heart, Lung, Blood and Vascular Medicine Institute, University of Pittsburgh, Pittsburgh PA 15261, USA.
Free Radic Biol Med. 2017 Apr;105:48-67. doi: 10.1016/j.freeradbiomed.2016.12.015. Epub 2016 Dec 16.
Recent insights into the bioactivation and signaling actions of inorganic, dietary nitrate and nitrite now suggest a critical role for the microbiome in the development of cardiac and pulmonary vascular diseases. Once thought to be the inert, end-products of endothelial-derived nitric oxide (NO) heme-oxidation, nitrate and nitrite are now considered major sources of exogenous NO that exhibit enhanced vasoactive signaling activity under conditions of hypoxia and stress. The bioavailability of nitrate and nitrite depend on the enzymatic reduction of nitrate to nitrite by a unique set of bacterial nitrate reductase enzymes possessed by specific bacterial populations in the mammalian mouth and gut. The pathogenesis of pulmonary hypertension (PH), obesity, hypertension and CVD are linked to defects in NO signaling, suggesting a role for commensal oral bacteria to shape the development of PH through the formation of nitrite, NO and other bioactive nitrogen oxides. Oral supplementation with inorganic nitrate or nitrate-containing foods exert pleiotropic, beneficial vascular effects in the setting of inflammation, endothelial dysfunction, ischemia-reperfusion injury and in pre-clinical models of PH, while traditional high-nitrate dietary patterns are associated with beneficial outcomes in hypertension, obesity and CVD. These observations highlight the potential of the microbiome in the development of novel nitrate- and nitrite-based therapeutics for PH, CVD and their risk factors.
最近对无机膳食硝酸盐和亚硝酸盐的生物活化及信号传导作用的深入了解表明,微生物群在心脏和肺血管疾病的发展中起关键作用。硝酸盐和亚硝酸盐曾被认为是内皮源性一氧化氮(NO)血红素氧化的惰性终产物,现在则被视为外源性NO的主要来源,在缺氧和应激条件下具有增强的血管活性信号传导活性。硝酸盐和亚硝酸盐的生物利用度取决于哺乳动物口腔和肠道中特定细菌群体所拥有的一组独特的细菌硝酸盐还原酶将硝酸盐酶促还原为亚硝酸盐的过程。肺动脉高压(PH)、肥胖、高血压和心血管疾病(CVD)的发病机制与NO信号传导缺陷有关,这表明共生口腔细菌可能通过亚硝酸盐、NO和其他生物活性氮氧化物的形成来影响PH的发展。在炎症、内皮功能障碍、缺血再灌注损伤以及PH的临床前模型中,口服补充无机硝酸盐或含硝酸盐的食物会产生多效性的有益血管作用,而传统的高硝酸盐饮食模式与高血压、肥胖和CVD的有益结果相关。这些观察结果突出了微生物群在开发用于治疗PH、CVD及其危险因素的新型硝酸盐和亚硝酸盐疗法方面的潜力。